Compare Hoechst Pakistan Ltd. with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
PKR 36,921 Million (Mid Cap)
17.00
NA
2.88%
-0.17
35.39%
4.51
Revenue and Profits:
Net Sales:
6,373 Million
(Quarterly Results - Dec 2025)
Net Profit:
689 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
7.65%
0%
7.65%
6 Months
22.36%
0%
22.36%
1 Year
122.34%
0%
122.34%
2 Years
375.32%
0%
375.32%
3 Years
305.24%
0%
305.24%
4 Years
252.2%
0%
252.2%
5 Years
321.35%
0%
321.35%
Hoechst Pakistan Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
17.02%
EBIT Growth (5y)
35.38%
EBIT to Interest (avg)
29.65
Debt to EBITDA (avg)
0.10
Net Debt to Equity (avg)
-0.29
Sales to Capital Employed (avg)
3.87
Tax Ratio
42.86%
Dividend Payout Ratio
79.82%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
44.09%
ROE (avg)
15.90%
Valuation key factors
Factor
Value
P/E Ratio
17
Industry P/E
Price to Book Value
5.64
EV to EBIT
7.67
EV to EBITDA
7.20
EV to Capital Employed
8.56
EV to Sales
1.25
PEG Ratio
0.43
Dividend Yield
2.65%
ROCE (Latest)
111.56%
ROE (Latest)
33.45%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
Dec'25
Sep'25
Change(%)
Net Sales
6,372.60
8,289.30
-23.12%
Operating Profit (PBDIT) excl Other Income
1,310.50
1,760.60
-25.57%
Interest
23.40
18.30
27.87%
Exceptional Items
0.00
0.00
Consolidate Net Profit
689.40
867.60
-20.54%
Operating Profit Margin (Excl OI)
189.60%
201.90%
-1.23%
USD in Million.
Net Sales
QoQ Growth in quarter ended Dec 2025 is -23.12% vs -4.94% in Sep 2025
Consolidated Net Profit
QoQ Growth in quarter ended Dec 2025 is -20.54% vs 9.85% in Sep 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
30,955.40
26,747.80
15.73%
Operating Profit (PBDIT) excl Other Income
6,053.50
3,359.80
80.17%
Interest
99.90
144.50
-30.87%
Exceptional Items
0.00
18.90
-100.00%
Consolidate Net Profit
2,900.10
1,857.10
56.16%
Operating Profit Margin (Excl OI)
184.10%
114.10%
7.00%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 15.73% vs 25.17% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 56.16% vs 414.72% in Dec 2024
About Hoechst Pakistan Ltd. 
Hoechst Pakistan Ltd.
Pharmaceuticals & Biotechnology
Sanofi-Aventis Pakistan Limited (Sanofi) is a Pakistan-based company, which is engaged in the manufacturing and selling of pharmaceutical and consumer products. The Company's segment is manufacturing and selling of pharmaceutical and consumer products. The Company offers medicines, consumer healthcare products, generics and animal health products. Its products include oral anti-diabetics, such as Amaryl and Amaryl M, Daonil and Daonil - M, and Neodipar; insulins, such as Lantus, Apidra and SoloSTAR; cancer, such as Jevtana, Taxotere, Eloxatin and Fludara; pain management, such as No-Spa, Gardan, Muscoril and Profenid; allergy management, such as Telfast, Avil, Nasacort, Phenergan and Avomine; cough and cold, such as Rhinathiol and Tixylix; sleep disorders, such as Stilnox; emergency care, such as Haemaccel; cardiology, such as Plavix, CoPlavix, Aprovel, Co Aprovel, Clexane, Tritace, Co Tritacem and Winstor, and antibiotics, such as Tarivid, Claforan, Aventriax and Rulid.
Company Coordinates 
Company Details
Plot No. 23, Sector No. 22, Korangi Industrial Area, KARACHI None : 74900
Registrar Details






